WEBULL
WebtradeDownload

CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value

Simply Wall St · 2d ago

CRISPR Therapeutics has seen its share price move around over the years, and the latest level leaves a clear question for anyone looking at the stock. Is the current market value actually in line with what its balance sheet and book value suggest the business is worth?

  • Over the past 5 years the share price has fallen 55.8%, which puts the focus squarely on whether the remaining equity on the balance sheet supports where the stock trades today.
  • For a biotech that still leans heavily on research, clinical progress and future treatment approvals to turn science into revenue, the strength of its equity base and how much capital it may need before reaching steady cash generation can heavily influence how you read its book value.
  • There is a second opinion on CRISPR Therapeutics worth weighing. See what analysts think CRISPR Therapeutics's shares could be worth.

For investors, the debate is whether the current share price for CRISPR Therapeutics is justified by the value of the net assets already sitting on its books when compared with the industry average.

If you are weighing whether CRISPR Therapeutics' recent share price and book value line up, it can help to compare that same question across solid balance sheet and fundamentals stocks screener (22 results).

Is CRISPR Therapeutics Getting Expensive on Book Value?

P/B suits CRISPR Therapeutics because the balance sheet still does a lot of the heavy lifting while the pipeline works toward commercial scale. On this yardstick, the stock trades at a P/B of about 2.9x compared with the broader Biotechs sector on roughly 2.2x and peers at around 11.3x, so the share price carries a premium to the industry but not to the wider peer group.

For you as a potential shareholder, that higher multiple versus the sector points to CRISPR Therapeutics being priced as overvalued on book value alone, since every dollar of equity here costs more than the average biotech. The key question is whether the research portfolio, clinical assets and future cash generation potential justify paying above the sector’s balance sheet benchmark or whether the current P/B already bakes in a lot of optimism. Explore the numbers behind CRISPR Therapeutics's P/B valuation.

NasdaqGM:CRSP P/B Ratio as at Sep 2026
NasdaqGM:CRSP P/B Ratio as at Sep 2026

The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

CRISPR Therapeutics' price puzzle on book value sets up the role of Simply Wall St Narratives. These map out what would need to happen to future growth, profitability and earnings for the shares to trade meaningfully higher or lower than today, and sit on the Community page for the stock. Where a single ratio or valuation model gives you one number, these frameworks spell out the future that number relies on so you can watch whether reality lines up with that path.

A written, number driven view on CRISPR Therapeutics helps pin down exactly which expectations about its growth, margins and execution need to hold true for today's valuation to keep making sense. It also gives you a reference point you can revisit as new trial data, partnerships and funding decisions show how closely the actual results track those original assumptions.

Share your own Narrative for CRISPR Therapeutics and set out the assumptions behind your valuation.

One more CRISPR Therapeutics factor that could shift the story

Before you stop at the balance sheet and valuation ratios, it is worth checking who is steering CRISPR Therapeutics, how their rewards line up with your interests, and what that says about future decisions. See who runs CRISPR Therapeutics and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.